19.12.2024 – 11:43RHEACELL GmbH und Co. KGRHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcersmore
16.12.2024 – 10:27Gerresheimer AGGerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*more
25.11.2024 – 13:52Helmholtz Zentrum MünchenInceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapiesmore
24.10.2024 – 08:09Ottobock SE & Co. KGaAOttobock invests in NeuroTech company ONWARD® MedicalOttobock Newsroommore
24.09.2024 – 12:25RHEACELL GmbH und Co. KGRHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVUmore
09.09.2024 – 09:06Sysmex Europe SE2Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.Visit our website!One documentmore
10.04.2024 – 11:00Dr. Reddy's Laboratories SADr. Reddy's subsidiary betapharm, and Theranica launch Nerivio® in Germany to provide patients with drug-free migraine treatmentmore
28.02.2024 – 15:00RHEACELL GmbH und Co. KGResearch Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘more
28.02.2024 – 11:07Helmholtz Zentrum MünchenRising Focus on 'Inceptor' as a Type 2 Diabetes Therapeutic Targetmore
26.01.2024 – 13:50Biomay AGBiomay Announces its Successful Support of Approval of First CRISPR/Cas9-based Therapymore
08.12.2023 – 11:13Helmholtz Zentrum MünchenNew Source of Stem Cells in Injury-Affected Brains of Patientsmore
30.08.2023 – 12:28STADA Arzneimittel AG2Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey revealsOne documentmore
09.08.2023 – 16:52Helmholtz Zentrum MünchenA New Ally in Fighting Brain Diseases: Our Very Own Skullmore
30.06.2023 – 10:09ARTTIC Innovation GmbH2CARAMBA: New Hope for Multiple Myeloma PatientsCARAMBA project websitemore
28.06.2023 – 17:13Helmholtz Zentrum MünchenNew Approach in Cancer Therapy With Innovative Mechanism-of-Action for Ferroptosis Inductionmore
27.06.2023 – 11:23RHEACELL GmbH und Co. KGRHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affectedmore
09.03.2023 – 10:00Medias Klinikum GmbH & Co KGThe world's first Extended Isolated Stopflow Limb Infusion (EISLI) to treat osteosarcoma results in complete remissionmore
09.11.2022 – 10:39RHEACELL GmbH und Co. KGStem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa researchmore
20.10.2022 – 12:00Klinik für Prostata-Therapie HeidelbergFocal therapy for prostate cancer: Reliable diagnosis leads to gentle treatmentmore
20.10.2021 – 16:30Sysmex Inostics GmbHNew Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inosticsmore
24.06.2021 – 17:28Helmholtz Zentrum MünchenGastrulation research reveals novel details about embryonic developmentmore
27.05.2021 – 10:35BrainRepair UGInvestment breakthrough for BrainRepair UG start-up – Stem cell treatment for newborns / Dr. Metin Colpan, founder of Nasdaq listed Qiagen N.V. acquired 5% of BrainRepair UG shares worth EUR 15Mmore
13.04.2021 – 14:04Fördergesellschaft IZB mbH2Lindis Biotech develops immunotherapy against bladder cancerIn the IZB you can find over 50 biotech start-upsOne documentmore
03.02.2021 – 13:30Fördergesellschaft IZB mbH3World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic toolsIn the IZB you can find over 50 biotech start-upsOne documentmore
15.01.2021 – 15:15Semdor Pharma GroupMerger: Newly-formed Semdor Pharma Group becomes one of Europe's leading pharmaceutical companies for narcotics and medical cannabismore
30.09.2020 – 13:00BrainRepair UGRegulatory breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns /EMA Orphan Drug Designation is followed by agreement on Paediatric Investigation Planmore
04.06.2020 – 14:16SYNformulas GmbH2Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipationmore
27.04.2020 – 17:22Helmholtz Zentrum München2Beta cells from stem cells: Potential for cell replacement therapyRead the studymore